Impress Secures €40M EIB Venture Debt
Spanish digital orthodontics company Impress signs a €40 million European Investment Bank venture-debt agreement to expand its AI-supported clinical network.
Scaling healthcare technology is not just a software problem when the business also operates physical clinics. Impress is using institutional debt financing to grow both parts of its orthodontics platform.
What happened
Barcelona-based Impress signed a €40 million venture-debt agreement with the European Investment Bank. The company plans to invest in its AI-enabled orthodontic platform and expand its clinic network, particularly in northern European markets.
Impress operates more than 110 clinics internationally, combining orthodontic treatment with digital planning, monitoring and clinical follow-up. It says its technology draws on a dataset of roughly 500,000 patients and helps reduce the need for in-person visits, although efficiency improvements are company-reported.
The loan follows earlier financing and expansion activity, including the acquisition of DrSmile. The new €40 million facility is debt financing, not a newly issued equity round or a government grant. Borrowing must ultimately be serviced or repaid under its agreed terms.
Why it matters
Impress represents a different healthcare AI model from startups that only sell software to hospitals. Its value proposition depends on integrating technology with treatment delivery, clinical staff and physical locations.
Debt financing may let a growing operator fund expansion without issuing as many new shares, but it also increases financial obligations. Investors and lenders will care about clinic utilisation, patient acquisition costs, clinical outcomes and cash generation.
The bigger picture
More mature European healthtech businesses are beginning to access financing associated with established infrastructure and services companies. That can diversify their growth capital, provided real operating performance—not AI branding alone—supports the borrowing.